Category Archive: Finance, No picture
SPX Reverses From All-Time High
VIX closed above Long-term resistance at 14.25, confirming a probable buy signal in the VIX. The Cycles Model shows a likely surge in strength for the VIX through mid-October. (Bloomberg) Strategists are predicting a pickup in volatility after an usually quiet August, seeing choppy waters ahead for traders who took a summer break. U.S. stock […]
Economic Data And Forecasts For The Weeks Of September 10 And 17
Here are my forecasts for upcoming economic data. Forecast Prior Observation Consensus Week of September 10 September 10 Consumer Credit – July $14.0B 10.2 14.0 September 11 NFIB Small Business Optimism Index […]
Looking Ahead To Q3 Earnings Season
In looking ahead to the Q3 earnings season here are the key points: Total earnings for the S&P 500 index are expected to be up +18.1% in Q3 from the same period last year on +7.2% higher revenues, the 6th time in the last 7 quarters of double-digit earnings growth. Q3 earnings growth is expected to […]
GBP: Positive Momentum Will Continue To Drive Sterling Higher
Fundamental Forecast for GBP: Bullish STERLING (GBP) TALKING POINTS: Sterling making gains against a range of currencies, but the US dollar remains stubbornly strong. Big week of data releases and the latest Bank of England meeting. The DailyFX Q3 GBP Forecast is available to download. We recently turned positive on Sterling and our view has been hardened this week, helped by a […]
Markets Fall Right On The Edge
Stocks fall to the edge of the expected move for the week once again showing how crucial these levels are that we discuss every week. In this crucial weekend video newsletter update we focus on what risks to watch for next week and what opportunities are ahead.
Week In Review: Jiangsu Hansoh To Raise Up To $3 Billion In Hong Kong IPO
Hansoh, a China pharma based in Lianyungang, Jiangsu province, has applied to stage an IPO on the Hong Kong exchange (see story). Unlike most companies seeking Hong Kong IPOs, Hansoh is both profitable and established. It claims to be one of the top 30 biopharmas in China, with revenues of $900 million in 2017. Two years ago, when rumors of a Hong Kong IPO […]
